Rexlemestrocel-L (Mesoblast/Teva Pharmaceutical Industries)

N/A

Report date: 2026/05/20 15:17:18

Base Information

Drug NameRexlemestrocel-L (Mesoblast/Teva Pharmaceutical Industries)
Drug Alias NameMesenchymal stem cell therapy (Mesoblast)Allogeneic mesenchymal precursor cells (Mesoblast)Allogeneic STRO-3 immunoselected bone marrowderived mesenchymal precursor cells (MPCs) (Mesoblast)ReplicartRevascor +[20] 
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionTissue replacementsOsteogenesis stimulantsStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsAnterior Cruciate Ligament InjuriesGraft vs Host DiseaseDiabetes Mellitus, Type 2 +[16] 
Global Approved IndicationsGraft vs Host Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2024/12/18
Country/TerritoryCanadaUnited StatesAustralia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesSa PathologyThe University Of Texas MD Anderson Cancer CenterHanson Institute +[5] 
China Registration ClassN/A

Develop Information

Active CompaniesMesoblast LtdBoston Children'S HospitalTasly Biomedical Co Ltd
Inactive CompaniesIcahn School Of Medicine At Mount SinaiNational Heart, Lung, And Blood Institute (Nhlbi)Mesoblast Inc +[4] 
Active IndicationsGraft vs Host DiseaseHypoplastic Left Heart SyndromeIntervertebral Disc Degeneration
Inactive IndicationsAnterior Cruciate Ligament InjuriesDiabetes Mellitus, Type 2Ventricular Dysfunction +[13] 

Other Information

ATC CodeN/A
Related LinksN/A